Takeda Pharmaceutical
✦ Quant Ownership Signal how this is computed
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q4).
- Total institutional ownership fell 1.2 percentage points.
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Institutional ownership
- Held by institutions
- 51.33% -1.15pp
- Institutions
- 728 -2
- As of
- 2026/Q4 vs. prior period
Holder types
Top holders as of 2026-10-15
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 19 buys · 31 sells
| Name | Role | Stake |
|---|---|---|
| Christophe P. Weber | Former President, CEO & Representative Director | 0.05% |
| Andrew S. Plump | President of Research & Development and Representative Director | 0.02% |
| Julie Kim | Chief Executive Officer | 0.01% |
| Giles Platford | President of International Business Unit | 0.01% |
| Teresa Marie Bitetti | President of the Global Oncology Business Unit | 0.00% |
| Marcello Pignagnoli Agosti | Interim Head of Strategy & Portfolio Development | 0.00% |
| Gabriele Ricci | Chief Data & Technology Officer | 0.00% |
| Lauren Duprey | Chief Transformation Officer | 0.00% |
| Milano Furuta | Chief Financial Officer | 0.00% |
| Farajallah Awny Botros | Chief Medical Officer | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-11-03 | Giles Platford | President of International Business Unit | Open Market Disposition | -55,617 | $20.90 |
| 2026-11-01 | Teresa Marie Bitetti | President of the Global Oncology Business Unit | Private Disposition | -46,609 | $0.13 |
| 2026-10-31 | Giles Platford | President of International Business Unit | Intent to Sell (Form 144) | -55,617 | $20.17 |
| 2026-09-13 | Lauren Duprey | Chief Transformation Officer | Open Market Disposition | -34,535 | $18.54 |
| 2026-09-01 | Andrew S. Plump | President of Research & Development and Representative Director | Automatic Disposition | -116,191 | $18.49 |
| 2026-08-18 | Andrew S. Plump | President of Research & Development and Representative Director | Automatic Disposition | -19,651 | $18.49 |
| 2026-08-17 | Nicola Greenway | -- | Open Market Disposition | -12,980 | $18.11 |
| 2026-08-13 | Nicola Greenway | -- | Intent to Sell (Form 144) | -12,980 | $17.39 |
| 2026-08-10 | Elaine Shannon | President of Global Supply & Quality | Open Market Disposition | -20,363 | $17.55 |
| 2026-08-09 | Andrew S. Plump | President of Research & Development and Representative Director | Private Disposition | -165,393 | $17.10 |
| 2026-08-09 | Giles Platford | President of International Business Unit | Private Disposition | -31,083 | $17.10 |
| 2026-08-09 | Farajallah Awny Botros | Chief Medical Officer | Private Disposition | -14,006 | $17.10 |
| 2026-08-09 | Julie Kim | Chief Executive Officer | Private Disposition | -89,090 | $17.10 |
| 2026-08-09 | Teresa Marie Bitetti | President of the Global Oncology Business Unit | Private Disposition | -50,012 | $17.10 |
| 2026-08-09 | Ramy Ibrahim | -- | Private Disposition | -7,277 | $17.10 |
| 2026-08-09 | Lauren Duprey | Chief Transformation Officer | Private Disposition | -47,586 | $17.10 |
| 2026-08-09 | Gabriele Ricci | Chief Data & Technology Officer | Private Disposition | -25,088 | $17.10 |
| 2026-08-09 | Marcello Pignagnoli Agosti | Interim Head of Strategy & Portfolio Development | Private Disposition | -22,957 | $17.10 |
| 2026-08-09 | Elaine Shannon | President of Global Supply & Quality | Private Disposition | -3,978 | $17.10 |
| 2026-08-09 | Natalie Furney | Global General Counsel | Private Disposition | -30,868 | $17.10 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-11-20 20:02:19 · For reference only, not investment advice and not tailored to your situation.
Takeda Pharmaceutical discussion 0 comments